Press Releases
Publications & Presentations
Events
Press Releases
July 29, 2020
Collaboration will focus on applying advanced RNA-based molecular technologies to predict disease progression and identify potential drug response biomarkers MANHATTAN BEACH, CA and DURHAM, N.C., July 29, 2020 — The Pancreatic Cancer…
March 23, 2020
GeneCentric Therapeutics is now located at 100 Capitola Dr, Suite275 Durham, NC 27713
March 23, 2020
GeneCentric Therapeutics continues to monitor the evolving novel Coronavirus (COVID-19) situation closely. We are following the Centers for Disease Control and Prevention (CDC) recommendations on prevention and spread of the virus along…
February 13, 2020
New molecular analyses to be presented at ASCO Genitourinary Cancers Symposium Durham, NC, February 13, 2020 – GeneCentric Therapeutics today announced it will present two posters during the ASCO GU Cancers Symposium…
August 15, 2019
Combined company uniquely suited to drive precision oncology forward with RNA technologies to identify oncology drug responder populations Durham, NC, August 15, 2019 – GeneCentric Therapeutics, Inc. today announced that it has…
August 9, 2019
Partners to initiate Second Phase of R01-Awarded Research Durham, NC, August 9, 2019 – GeneCentric Therapeutics, Inc. today announced that it has entered the second phase of an academic-industry collaboration with Jose…
June 3, 2019
GeneCentric Therapeutics will present the first data on novel response signatures for metastatic, muscle invasive bladder cancer (MIBC) treatments by applying its proprietary, RNA-sequencing based predictive response signature and Cancer Subtyping Platform…
February 18, 2019
GeneCentric Therapeutics, Inc. collaborator Dr. Tracy Rose from the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC presented at the Genitourinary Cancers Symposium today on: “Fibroblast growth factor receptor status and response…
January 3, 2019
CEO Dr. Myla Lai-Goldman named Executive Chairperson Durham, NC, January 3, 2019 -GeneCentric Therapeutics, Inc. today announced the appointment of Michael V. Milburn, PhD, as Chief Executive Officer and President and will…
December 10, 2018
Focus is on advancing cancer subtypes to predict disease progression and pursuing immune-biology related drug response biomarkers DURHAM, N.C., December 10, 2018 — GeneCentric Therapeutics, Inc. today announced that it has entered…
Publications & Presentations
Comprehensive molecular profiling of lung adenocarcinoma
April 22, 2014
Comprehensive genomic characterization of squamous cell lung cancers
September 27, 2012
Events
No results found.